Company
Kira Biotech
Kira Biotech is an Australian biotechnology company developing immunomodulatory therapies for immune system disorders. Its lead program, KB312, is a monoclonal antibody targeting activated immune cells to restore immune tolerance. The company is progressing KB312 through preclinical development and phase 1 clinical trials, with an initial focus on acute graft-versus-host disease. The board chair is Michael Grissinger, a former executive at Johnson & Johnson, and the CEO is Dr.
Investors
Investor